Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with geftinib or erlotinib

Experimental and Therapeutic Medicine

Volumn 2, Issue 4, 2011, Pages 685-693

  Jung, Minkyu ^a,b   Kim, Se Hyun ^a   Lee, Young Joo ^a   Hong, Soojung ^a   Kang, Young Ae ^a   Kim, Se Kyu ^a   Chang, Joon ^a   Rha, Sun Young ^a   Kim, Joo Hang ^a   Kim, Dae Joon ^a   Cho, Byoung Chul ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Gachon University College of Medicine   (South Korea)

Author keywords

Biological markers; Carcinoembryonic antigen; Carcinoma; Cytokeratin 19 fragments; Non small cell lung cancer; Tyrosine kinase inhibitor

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; MUTANT PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; FEMALE; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SEX DIFFERENCE; SMOKING; TREATMENT RESPONSE;

EID: 79958038844     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.273     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
2. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132, 2005.
3. Kim ES, Hirsh V, Mok T, et al: Geftinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372: 1809-1818, 2008.
4. Mok TS, Wu Y, Thongprasert S, et al: Geftinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957, 2009.
5. Maheswaran S, Sequist LV, Nagrath S, et al: Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359: 366-377, 2008.
6. Molina R, Auge JM, Escudero JM, et al: Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as tumor markers in patients with lung cancer: comparison with CYFRA 21-1, CEA, SCC and NSE. Tumour Biol 29: 371-380, 2008.
7. Okada M, Nishio W, Sakamoto T, et al: Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer: analysis of 1,000 consecutive resections for clinical stage I disease. Ann Thorac Surg 78: 216-221, 2004.
8. Pujol JL, Boher JM, Grenier J and Quantin X: CYFRA 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Lung Cancer 31: 221-231, 2001.
9. Holdenrieder S, von Pawel J, Dankelmann E, et al: Nucleosomes and CYFRA 21-1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer. Lung Cancer 63: 128-135, 2009.
10. Ardizzoni A, Cafferata MA, Tiseo M, et al: Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced non-small cell lung cancer. Cancer 107: 2842-2849, 2006.
11. Okamoto T, Nakamura T, Ikeda J, et al: Serum carcinoembry onic antigen as a predictive marker for sensitivity to geftinib in advanced non-small cell lung cancer. Eur J Cancer 41: 1286-1290, 2005.
12. Barlsi F, Tchouhadjian C, Doddoli C, Torre JP, Astoul P and Kleisbauer JP: CYFRA 21-1 level predicts survival in non-small cell lung cancer patients receiving geftinib as third-line therapy. Br J Cancer 92: 13-14, 2005.
13. Chiu C, Shih Y, Tsai C, Liou J, Chen Y and Perng R: Serum tumor markers as predictors for survival in advanced non-small cell lung cancer patients treated with geftinib. Lung Cancer 57: 213-221, 2007
14. Travis WD, Colby TV, Corrin B, Shimosato Y and Brambilla E. (eds): Histological Typing of Lung and Pleural Tumours. 3rd edition. Springer-Verlag, Berlin, 1999. 26.
15. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
16. Han S, Kim T, Hwang PG, et al: Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with geftinib. J Clin Oncol 23: 2493-2501, 2005.
17. Gold P and Freedman SO: Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 121: 439-462, 1965.
18. Fujishima T, Honda Y, Shijubo N, Takahashi H and Abe S: Increased carcinoembryonic antigen concentrations in sera and bronchoalveolar lavage fluids of patients with pulmonary alveolar proteinosis. Respiration 62: 317-321, 1995
19. Rule AH, Straus E, Vandevoorde J and Janowitz HD: Tumor- associated (CEA-reacting) antigen in patients with inflammatory bowel disease. N Engl J Med 287: 24-26, 1972. 32.
20. Okada M, Nishio W, Sakamoto T, et al: Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma. Ann Thorac Surg 78: 1004-1009, 2004.
21. Matsuoka K, Sumitomo S, Nakashima N, Nakajima D and Misaki N: Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer. Eur J Cardiothorac Surg 32: 435-439, 2007.
22. Shoji F, Yoshino I, Yano T, et al: Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas. Cancer 110: 2793-2798, 2007.
23. Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K and Stanners CP: Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 57: 327-334, 1989.
24. Hammarström S: The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 9: 67-81, 1999
25. Screaton RA, Penn LZ and Stanners CP: Carcinoembryonic antigen, a human tumor marker, cooperates with Myc and Bcl-2 in cellular transformation. J Cell Biol 137: 939-952, 1997
26. Ordoez C, Screaton RA, Ilantzis C and Stanners CP: Human carcinoembryonic antigen functions as a general inhibitor of anoikis. Cancer Res 60: 3419-3424, 2000.
27. Stieber P, Bodenmller H, Banauch D, et al: Cytokeratin 19 fragments: a new marker for non-small cell lung cancer. Clin Biochem 26: 301-304, 1993.
28. Nisman B, Lafair J, Heching N, et al: Evaluation of tissue poly-peptide-specific antigen, CYFRA 21-1, and carcinoembryonic antigen in non small cell lung carcinoma: Does the combined use of cytokeratin markers give any additional information? Cancer 82: 1850-1859, 1998.
29. Barlsi F, Gimenez C, Torre J, et al: Prognostic value of combination of CYFRA 21-1, CEA and NSE in patients with advanced non-small cell lung cancer. Respir Med 98: 357-362, 2004.
30. Pujol JL, Molinier O, Ebert W, et al: CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer 90: 2097-2105, 2004
31. Kao CH, Hsieh JF, Ho YJ, Tsai SC and Lee JK: Cytokeratin fragment 19 (CYFRA 21-1) in healthy smokers. Anticancer Res 19: 4545-4546, 1999.
32. Molina R, Filella X, Aug JM, et al: Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol 24: 209-218, 2003.
33. Shigematsu H, Lin L, Takahashi T, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97: 339-346, 2005.